Nucleix Ltd., a Rehovot, Israel-based company that develops, manufactures and markets innovative non-invasive molecular cancer diagnostic tests, raised $3m in funding.
Backers included OrbiMed Israel Partners, Aurum Ventures MKI, and Zohar Zisapel.
The company is using the funds to continue to advance its tests and hire new people.
Nucleix develops cancer detection tests based on identification of subtle changes in methylation patterns, which leverage proprietary technology based on a combination of a new biochemical platform in conjunction with algorithms.
The first product Bladder EpiCheck® is a urine test for monitoring of bladder cancer, which is expected to reach the market in Q3 2016.
The company’s pipeline includes diagnostic tests for lung and colorectal cancer detection from blood samples.